tradmap

HRTX Earnings HERON THERAPEUTICS, INC. /DE/

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Latest filing

Annual results

Diluted EPS (annual)
-$2 -$1 $0 2021 2022 2023 2024 2025
EPS
Revenue (annual)
$0 $77M $155M 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Revenue
Net income (annual)
-$227M -$114M $0 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Net income

Quarterly results

Diluted EPS (quarterly)
-$0 -$0 $0 $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
EPS
Revenue (quarterly)
$0 $20M $41M Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Revenue
Net income (quarterly)
-$25M -$11M $4M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income

Reported EPS history

1–25 of 25
Q2 20262026-06-30-0.032026-08-1010-Q
Q1 20262026-03-31-0.042026-05-1110-Q
Q4 2025 (derived)2025-12-31-0.012026-02-2610-K
FY 20252025-12-31-0.122026-02-2610-K
Q3 20252025-09-30-0.102025-11-0410-Q
Q2 20252025-06-30-0.022025-08-0810-Q
Q1 20252025-03-310.012025-05-0610-Q
Q4 2024 (derived)2024-12-310.022025-02-2710-K
FY 20242024-12-31-0.092025-02-2710-K
Q3 20242024-09-30-0.032024-11-1210-Q
Q2 20242024-06-30-0.062024-08-0610-Q
Q1 20242024-03-31-0.022024-05-0710-Q
Q4 2023 (derived)2023-12-31-0.012024-03-1210-K
FY 20232023-12-31-0.802024-03-1210-K
Q3 20232023-09-30-0.172023-11-1410-Q
Q2 20232023-06-30-0.352023-08-1410-Q
Q1 20232023-03-31-0.272023-05-1110-Q
Q4 2022 (derived)2022-12-31-0.112023-03-2910-K
FY 20222022-12-31-1.672023-03-2910-K
Q3 20222022-09-30-0.382022-11-0810-Q
Q2 20222022-06-30-0.552022-08-0910-Q
Q1 20222022-03-31-0.63——
FY 20212021-12-31-2.24——
Q3 20212021-09-30-0.51——
Q2 20212021-06-30-0.62——

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Q4 EPS marked "derived" is computed as the fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive across quarters, so it can differ by a cent or two from the issuer's own Q4. A period with no "Reported" date is known only from a later filing's prior-year comparative. Informational only — not financial advice.